Troglitazone Suppresses Cell Growth of Myeloid Leukemia Cell Lines by Induction of p21WAF1/CIP1 Cyclin-Dependent Kinase Inhibitor
- 11 August 1999
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 261 (3), 833-837
- https://doi.org/10.1006/bbrc.1999.1049
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDLCell, 1998
- Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein SlimbNature, 1998
- The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activationNature, 1998
- Glucocorticoid Inhibition of Fibroblast Proliferation and Regulation of the Cyclin Kinase Inhibitor p21Cip1Molecular Endocrinology, 1997
- Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes.Endocrinology, 1996
- Thiazolidinediones and Fatty Acids Convert Myogenic Cells into Adipose-like CellsPublished by Elsevier BV ,1995
- Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with TroglitazoneThe New England Journal of Medicine, 1994
- Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cellsAmerican Journal of Physiology-Cell Physiology, 1993
- Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM SubjectsDiabetes Care, 1992
- Ciglitazone, a New Hypoglycemic Agent: I. Studies in ob/ob and db/db Mice, Diabetic Chinese Hamsters, and Normal and Streptozotocin-Diabetic RatsDiabetes, 1983